Physician profile
Khalid Rauf
NPI 1700802709
$7,355.64
in general payments reported to CMS, 2019-2025
34 companies · $1,300 in 2025
The $1,300 reported for 2025 was more than what 76% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,384 · 2020: $1,104 · 2021: $1,232 · 2022: $1,069 · 2023: $199 · 2024: $1,067 · 2025: $1,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,095 · Education: $271 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,094.66 |
| Education | $271.25 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,493.57 | 2019-2025 | Trelegy Ellipta, Nucala |
| Grifols USA, LLC | $1,003.50 | 2019-2022 | |
| Harmony Biosciences LLC | $774.82 | 2020-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $605.09 | 2019-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $560.40 | 2019-2025 | Tezspire |
| Jazz Pharmaceuticals INC. | $499.09 | 2019-2024 | Xywav |
| Bayer Healthcare Pharmaceuticals INC. | $386.68 | 2019-2024 | |
| United Therapeutics Corporation | $317.82 | 2019-2025 | Tyvaso |
| Regeneron Healthcare Solutions, INC. | $182.20 | 2021-2025 | Dupixent |
| Sunovion Pharmaceuticals INC. | $172.80 | 2019 | |
| Verona Pharma, INC. | $169.18 | 2025 | Ohtuvayre |
| Insmed, INC. | $136.46 | 2025 | Arikayce, Brinsupri |
| Advanced Respiratory, INC | $124.89 | 2019-2021 | |
| Philips North America LLC | $124.36 | 2019-2022 | |
| Genzyme Corporation | $102.86 | 2021-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $102.86 | 2020-2021 | |
| Fisher & Paykel Healthcare INC | $83.98 | 2022-2025 | Fisher & Paykel Healthcare |
| Mylan Specialty L.P. | $60.69 | 2019-2022 | |
| Olympus America INC. | $49.05 | 2024 | Spiration Valve System |
| Avadel Cns Pharmaceuticals, LLC | $48.33 | 2025 | Lumryz |
| Takeda Pharmaceuticals U.S.A., INC. | $47.99 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $40.08 | 2021-2022 | |
| Genentech USA, INC. | $39.99 | 2019-2022 | |
| Exact Sciences Corporation | $26.22 | 2025 | The Cologuard Plus Collection Kit |
| Abbott Laboratories | $25.16 | 2020 | |
| Resmed Corp | $24.65 | 2025 | |
| Novo Nordisk INC | $24.46 | 2019-2021 | |
| Axsome Therapeutics, INC. | $24.13 | 2024 | Sunosi |
| Mayne Pharma Commercial LLC | $21.94 | 2022 | |
| Shield Therapeutics INC | $20.10 | 2025 | |
| Medtronic USA, INC. | $18.95 | 2019 | |
| Lilly USA, LLC | $17.66 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.72 | 2019 | |
| Allergan, INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Rauf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.